STCube to Present Research Results on 'Glycation-Specific Immune Checkpoint Inhibitor PD-1 Antibody' at AACR

[Asia Economy Reporter Hyunseok Yoo] STCube, a bio company developing immune checkpoint inhibitors, announced on the 7th that it will present preclinical results of its core immune checkpoint inhibitor pipeline STM418 at the American Association for Cancer Research (AACR) conference to be held online in June.

STM418, a new drug candidate for immune checkpoint inhibitors, is an antibody that specifically recognizes the glycosylation of the immune checkpoint protein PD-1. STCube focused on the fact that the glycosylation sites of PD-1 affect stability and binding affinity, and through research discovered that among the four glycosylation sites of PD-1, the N58 site binds more strongly to PD-L1.

The STM418 antibody developed by STCube induces immune cell proliferation more actively than other FDA-approved PD-1 antibodies and also shows higher secretion of interferon-gamma, a signaling molecule that regulates and stimulates immune cells. Animal experiments with STM418 showed no safety issues, significantly inhibited tumor growth compared to other PD-1 antibodies, and confirmed prolonged survival in cancer-bearing animals.

The research results on STM418, which specifically recognizes glycosylated PD-1, were published in March in the world-renowned cancer research journal Cancer Research, and due to the excellence of the research and the potential of the STM418 antibody, it will be presented at the AACR conference.

This content was produced with the assistance of AI translation services.